Get the latest market trends in your inbox
Stay on top of the latest market trends and economic insights with the Axios Markets newsletter. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Minneapolis-St. Paul
Tampa-St. Petersburg news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa-St. Petersburg
Fernando Vergara / AP
The Food and Drug Administration designated the drug MDMA, known as Ecstasy, a "breakthrough therapy" for PTSD treatment earlier this month. The designation will expedite the agency's review of the drug, depending on the outcome of a clinical trial to test its effect versus that of standard psychotherapy. Ecstasy is in the DEA's category of Schedule 1 drugs, meaning that it is among substances with the highest potential for abuse, like heroin.
Why it matters: 11-20% of veterans who served in Afghanistan or Iraq suffer from PTSD, per the Department of Veterans' Affairs, and it is this group in particular that researchers hope ecstasy can help.
- "We're in this odd situation where one of the most promising therapies also happens to be a Schedule 1 substance," former Brig. Gen. Loree Sutton said to the Washington Post.
- "This is not a big scientific step ... It's been obvious for 40 years that these drugs are medicine. But it's a huge step in acceptance," David Nutt, a scientist at Imperial College London, told Science.
- One concern is that approving Ecstasy for PTSD will embolden groups seeking to legalize the drug for recreational use, the Post reports.